How do you counsel and manage around gastrointestinal toxicity when considering tirzepatide with ixekizumab in an adult with moderate to severe psoriasis?

PMID 42139049 The recent Phase 3b TOGETHER-PsO and TOGETHER-PsA trial data highlighted the substantial synergistic benefits of combining targeted IL-17A blockade (ixekizumab) with dual GIP/GLP-1 receptor agonism (tirzepatide) in adults with moderate-to-severe plaque psoriasis and comorbid obesity, delivering significant gains in complete skin clearance (PASI 100) and cardiometabolic endpoints. However, combining these therapies introduces a unique gastrointestinal counseling and monitoring challenge. Therefore, how would you differentiate between benign dysmotility vs IBD?